Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br Regulation of V ATPase
2025-01-02
Regulation of V-ATPase assembly in response to changes in amino Dehydroandrographolide levels A central regulator of cell growth and metabolism is mTORC1 [38]. mTORC1 integrates signals from nutrient availability and growth factor receptors to control such processes as protein and lipid synthesis
-
AP activation is known to
2025-01-02
AP-1 activation is known to upregulate downstream target genes including 3230 D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered by 15-HETE in the
-
Many ruthenium complexes were tested as potential anticancer
2025-01-02
Many ruthenium complexes were tested as potential anticancer agents and two complexes, namely NAMI-A (trans-[imH] [RuCl4(dmso-S)(im)]; im, imidazole) and KP1019 (trans-[indH][RuCl4(ind)2]; ind, indazole) have successfully entered clinical trials [27], [28]. NAMI-A is selectively active against metas
-
Recent progress has been made in translating animal findings
2025-01-02
Recent progress has been made in translating animal findings on memory performance and amnestic effects – that are largely determined by tonically active receptors in which α5 contributes to the benzodiazepine binding site. Based on the observation that deletion of this subunit led to improved spat
-
The evaluation of serum electrolytes e g
2025-01-02
The evaluation of serum electrolytes (e.g.: sodium, potassium, urea, creatinine, and uric acid), liver transaminases, blood counts (e.g. identification of thrombocytopenia, and bilirubin), 24-h urine (in order to monitor proteinuria), and heart rate and lung function of the mother should be performe
-
Dual acting RAAS blockade and neprilysin inhibition has
2025-01-02
Dual-acting RAAS blockade and neprilysin inhibition has been evaluated in several clinical HF trials. In PARADIGM-HF [6,7], LCZ696 was superior to enalapril in reducing mortality and HF hospitalizations in symptomatic patients with HF with reduced EF. Augmented benefits on maladaptive cardiac remode
-
3466 In the largest postmortem study of autopsied individual
2025-01-02
In the largest postmortem study of 3618 autopsied individuals, almost 75% of the individuals without Aβ pathology already harbored cortical NFT pathology mostly confined to the medial temporal regions (Murray et al., 2015). In Braak's study of 2366 autopsied individuals (Braak and Del Tredici, 2014)
-
br Results br Discussion Using primarily an electrophysiolog
2025-01-02
Results Discussion Using primarily an electrophysiological analysis of dysbindin-deficient hippocampal neurons in cultures and slices, we have uncovered a previously unreported role for dysbindin in enhancing CA3–CA1 AMPAR-mediated transmission. An earlier study, however, has reported a reduct
-
For hippocampal asymmetry two SNPs rs and
2025-01-02
For hippocampal asymmetry, two SNPs (rs1476679 and rs4147929) showed significant interaction with diagnosis. They have an inverse effect on asymmetry, which is consistent with their different roles as preventative or risk loci in AD. rs1476679 is intronic in the ZCWPW1 gene, is a histone modificatio
-
The role of the adaptive immune response in AD is
2025-01-02
The role of the adaptive immune response in AD is not fully understood and previous studies are controversial. In this context, serum levels of T and B lymphocytes were found to be reduced in AD patients, suggesting a decline of the immune response during the course of the disease (Richartz-Salzburg
-
br Translational Considerations Targeting the AHR Pathway Mo
2024-12-31
Translational Considerations Targeting the AHR Pathway Modulating AHR function offers exciting therapeutic potential in host immunity and inflammation. However, the emerging concept of AHR function in a cell type-specific manner, combined with differences between AHR activation in cell culture in
-
br Rapid nongenomic effects of corticosterone in an
2024-12-31
Rapid nongenomic effects of corticosterone in an amphibian model Studies in the model organism, the roughskin newt, Taricha granulosa, over 30 years ago led to the discovery that stress can rapidly (within minutes) suppress sexual behavior (amplectic clasping) of male T. granulosa, an effect that
-
In eukaryotes class III ACs including GCs
2024-12-31
In eukaryotes, class III ACs (including GCs) are almost universally present, with the noteworthy exception of higher plants. Our dataset comprises 9690 sequences of class III nucleotide cyclases from 710 eukaryotic species. Approximately 80% thereof belong to subclass IIIa and 10% to subclasses IIIb
-
It has been known that LOX is the rate limiting
2024-12-31
It has been known that 5-LOX is the rate-limiting enzyme for the products of LTs, and LTs actively participate in the activation of neutrophils [10]. In our study, we determined whether 5-LOX was upregulated in pancreatic tissues during ANP. Moreover, we investigated whether the inhibition of expres
-
Small kinase inhibitors have been developed to block AXL by
2024-12-31
Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha
15688 records 30/1046 page Previous Next First page 上5页 2627282930 下5页 Last page